Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mediclore is a poloxamer-based thermosensitive sol-gel anti-adhesion barrier developed by CGBio. It is composed of a mixture of Poloxamer 407, Poloxamer 188, and Sodium Alginate. The formulation is unique for its temperature-dependent phase transition: it remains a low-viscosity liquid (sol) at room temperature, facilitating easy application to complex surgical sites, and transforms into a highly viscous gel at body temperature. This gel serves as a physical barrier to prevent tissue surfaces from adhering during the healing process. Mediclore is primarily used in spinal surgeries to prevent epidural fibrosis and in breast cancer surgeries involving axillary lymph node dissection to reduce the risk of restricted shoulder motion and axillary web syndrome. It is currently marketed in South Korea for various surgical applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mediclore.